ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

Blumenthal Names Presidential Advisor; Groups Lobby To Limit Her Influence

October 3, 1997

NCI, American Cancer Society Re-Evaluating Join Guidelines On Mammography Screening

September 17, 1993

Klausner To Revamp NCI Budget Process To Make Categories Mean What They Say

December 8, 1995

ACS Supports NCI’s Bypass Budget In Resolution

March 20, 1992

Cancer Groups Fear Clinical Trials Coverage Will Not Be Implemented Across Exchanges

July 3, 2013

In the States: Arizona Approves Legislation on Patient Care Costs in Trials

May 5, 2000